Peptides 101: What They Are, Who They're For, and What the Evidence Actually Says
What Are Peptides?
A peptide is a short chain of amino acids — the same building blocks that make up proteins. If proteins are sentences, peptides are words. They're smaller, more targeted, and they act as signaling molecules in your body, telling cells what to do.
Your body already produces thousands of peptides naturally. Insulin is a peptide. Oxytocin is a peptide. The endorphins that make you feel good after a run are peptides. They're fundamental to how your body operates — not exotic or experimental at a basic biological level.
What makes peptide therapy interesting is the idea of using specific synthetic peptides to enhance or modulate processes your body already runs — healing, hormone production, immune function, metabolism, and more.
Why Are Peptides Suddenly Everywhere?
Three things converged. First, the science matured — researchers identified hundreds of peptides with specific biological activity, and a handful showed genuinely promising results in clinical and preclinical studies. Second, the telehealth boom made access easier — you can now consult with a peptide-prescribing physician from your couch. Third, the gray market exploded — companies selling “research peptides” directly to consumers created a massive, unregulated market that the FDA eventually cracked down on in 2023–2024.
That crackdown — the Category 2 reclassification — restricted compounding of 19 popular peptides. The situation has been evolving rapidly since: in April 2026, the FDA removed 12 of those peptides from Category 2 ahead of formal review, with PCAC meetings scheduled for July 23–24, 2026. None of those 12 are legally compoundable yet, but the regulatory landscape is moving for the first time in years. If you're confused about what's legal and what isn't right now, you're not alone — that's why we built the Regulatory Tracker.
The Categories That Matter
Peptides in therapeutic use generally fall into these outcome categories — this is how we organize our knowledge base, because consumers search for solutions to problems, not for molecule names. Some compounds also have evidence for secondary use cases — those tiers appear on individual compound profile pages, even when the compound is listed under a different primary category here.
Immune & Gut Health
Mood & Anxiety
Sleep & Recovery
Sexual Health
Weight Management
Skin & Hair
A note on what we don't have categories for: You may have read about peptides marketed for “longevity” or “growth hormone optimization.” We don't use those as categories because they're not concrete consumer outcomes — they're marketing rebrands of more specific goals (better sleep, better recovery, better skin, better metabolic health). When a peptide is marketed for longevity, ask which of those concrete outcomes it actually supports, then look it up under that category.
How We Rate the Evidence
Not all peptide evidence is created equal. This is the single most important thing to understand, and the thing most peptide content deliberately obscures. We use a three-tier framework:
Strong Evidence — FDA-approved or backed by large-scale human randomized controlled trials. You can make decisions with reasonable confidence. Example: Semaglutide.
Emerging Evidence — Limited human trials but strong animal data and growing clinical use. Promising but proceed with informed caution. Example: BPC-157, CJC-1295/Ipamorelin.
Early / Anecdotal — Primarily animal studies, case reports and community experience. Interesting but unproven. Example: Dihexa, PE-22-28.
Key point: we assign tiers per use case, not per compound. BPC-157 might be T2 for tendon repair but T3 for gut health. That granularity matters.
The Regulatory Landscape in 2026
This is complicated and changing. The short version:
In 2023–2024, the FDA placed 19 popular peptides on the Category 2 list, effectively restricting their compounding. On April 22, 2026, 12 of those peptides were removed from Category 2 ahead of formal PCAC review — but removal from Category 2 is not the same as legal to compound. The PCAC must review each compound, and the FDA must complete formal rulemaking before they can be added to the 503A bulks list. Meetings are scheduled for July 23–24, 2026 (BPC-157, TB-500, KPV, MOTS-C, DSIP, Semax, Epitalon) and before February 2027 (GHK-Cu, Melanotan II, LL-37, Dihexa, PEG-MGF).
Five other peptides — CJC-1295, Ipamorelin, AOD-9604, Thymosin Alpha-1, and Selank — were removed from Category 2 in September 2024 but PCAC voted against four of them at the December 2024 review.
Meanwhile, GLP-1 medications like semaglutide and tirzepatide are on a completely separate regulatory track — they're FDA-approved drugs where compounding has been restricted because the drug shortage has ended. Don't conflate these two situations.
For current status on any compound, check our Regulatory Tracker.
How Do I Find a Legitimate Peptide Provider?
If you're considering peptide therapy, the most important decision isn't which peptide — it's which provider. Look for:
- Licensed physician with peptide-specific experience
- Required lab work before prescribing
- Use of licensed compounding pharmacies (503A or 503B)
- Transparent pricing
- Willingness to discuss evidence limitations honestly
Red flags:
- No lab work required
- “Research peptide” sourcing
- Pressure to start multiple compounds immediately
- Inability to explain the evidence tier of what they’re prescribing
For more on how we evaluate evidence and providers, see Why We're Different.